Business Description
Crinetics Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US22663K1079
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 16.42 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.17 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 27.52 | |||||
Beneish M-Score | -3.34 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16.2 | |||||
3-Year EPS without NRI Growth Rate | -15.1 | |||||
3-Year FCF Growth Rate | -13 | |||||
3-Year Book Growth Rate | 15.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | -6.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 121.37 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.46 | |||||
9-Day RSI | 45.15 | |||||
14-Day RSI | 46.07 | |||||
6-1 Month Momentum % | 26.18 | |||||
12-1 Month Momentum % | 66.15 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 16.38 | |||||
Quick Ratio | 16.38 | |||||
Cash Ratio | 16.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.4 | |||||
Shareholder Yield % | -9.84 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -29525.22 | |||||
Net Margin % | -26747.83 | |||||
FCF Margin % | -19413.85 | |||||
ROE % | -38.33 | |||||
ROA % | -33.66 | |||||
ROIC % | -351.41 | |||||
ROC (Joel Greenblatt) % | -536.13 | |||||
ROCE % | -39.49 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3851.43 | |||||
PB Ratio | 5.23 | |||||
Price-to-Tangible-Book | 5.23 | |||||
EV-to-EBIT | -13.66 | |||||
EV-to-EBITDA | -13.76 | |||||
EV-to-Revenue | 4033 | |||||
EV-to-Forward-Revenue | 642.81 | |||||
EV-to-FCF | -20.58 | |||||
Price-to-Net-Current-Asset-Value | 5.64 | |||||
Price-to-Net-Cash | 5.75 | |||||
Earnings Yield (Greenblatt) % | -7.32 | |||||
FCF Yield % | -4.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Crinetics Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.96 | ||
EPS (TTM) (€) | -3.419 | ||
Beta | 0.08 | ||
Volatility % | 27.94 | ||
14-Day RSI | 46.07 | ||
14-Day ATR (€) | 1.193555 | ||
20-Day SMA (€) | 52.955 | ||
12-1 Month Momentum % | 66.15 | ||
52-Week Range (€) | 30.8 - 58.5 | ||
Shares Outstanding (Mil) | 92.74 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Crinetics Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Crinetics Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Crinetics Pharmaceuticals Inc Frequently Asked Questions
What is Crinetics Pharmaceuticals Inc(STU:6Z4)'s stock price today?
When is next earnings date of Crinetics Pharmaceuticals Inc(STU:6Z4)?
Does Crinetics Pharmaceuticals Inc(STU:6Z4) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |